ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
l
|
13K |
5.0M |
7 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
13K
|
5.0M
|
7
|
|
Charts
|
MSB |
Re:
MSB Charts
|
|
l
|
888 |
649K |
2 |
26/11/20 |
26/11/20 |
Charts
|
888
|
649K
|
2
|
|
NZX - By Stock
|
PEB |
Re:
Ann: HALFYR: PEB: Pacific Edge Unaudited Financial Results to 30 Sept 2020
|
|
l
|
8 |
2.2K |
0 |
26/11/20 |
26/11/20 |
NZX - By Stock
|
8
|
2.2K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
TYPE A OUTCOME AND NOVARTIS PARTNERSHIP
|
|
l
|
111 |
56K |
6 |
21/11/20 |
21/11/20 |
ASX - By Stock
|
111
|
56K
|
6
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Strategic partnership with Afterpay
|
|
l
|
113 |
33K |
0 |
13/11/20 |
13/11/20 |
ASX - By Stock
|
113
|
33K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Strategic partnership with Afterpay
|
|
l
|
113 |
33K |
2 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
113
|
33K
|
2
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Business Update Investor Presentation
|
|
l
|
29 |
9.0K |
0 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
29
|
9.0K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Business Update Investor Presentation
|
|
l
|
29 |
9.0K |
1 |
15/10/20 |
15/10/20 |
ASX - By Stock
|
29
|
9.0K
|
1
|
|
NZX - By Stock
|
PEB |
Re:
Ann: GENERAL: PEB: Pacific Edge Joins S&P / NZX 50 Index
|
|
l
|
8 |
2.2K |
2 |
15/10/20 |
15/10/20 |
NZX - By Stock
|
8
|
2.2K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Company Update - Webcast and Forward Thoughts
|
|
l
|
273 |
129K |
25 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
273
|
129K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
|
|
l
|
425 |
193K |
6 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
425
|
193K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Annual Financial Results and Operational Progress
|
|
l
|
53 |
25K |
3 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
53
|
25K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
l
|
11K |
3.5M |
1 |
23/08/20 |
23/08/20 |
ASX - By Stock
|
11K
|
3.5M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
l
|
13K |
5.0M |
29 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
13K
|
5.0M
|
29
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB - Most exciting 6 months
|
|
l
|
729 |
375K |
12 |
15/08/20 |
15/08/20 |
ASX - By Stock
|
729
|
375K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
l
|
2.0K |
700K |
4 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
700K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
l
|
2.0K |
700K |
5 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
700K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
l
|
2.0K |
700K |
12 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
700K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
l
|
2.0K |
700K |
3 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
700K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Anyone else buy in after todays dip/crash?
|
|
l
|
211 |
89K |
14 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
211
|
89K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
BLA 125706 Remestemcel-L FDA briefing document
|
|
l
|
41 |
22K |
2 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
41
|
22K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
l
|
854 |
434K |
7 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
434K
|
7
|
|
NZX - By Stock
|
PEB |
Re:
Ann: GENERAL: PEB: PEB Attracts Growth Capital at Market Premium
|
|
l
|
2 |
1.3K |
0 |
24/07/20 |
24/07/20 |
NZX - By Stock
|
2
|
1.3K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Quarterly Update
|
|
l
|
39 |
12K |
0 |
22/07/20 |
22/07/20 |
ASX - By Stock
|
39
|
12K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
l
|
18K |
7.0M |
4 |
18/07/20 |
18/07/20 |
ASX - By Stock
|
18K
|
7.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
l
|
518 |
268K |
2 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
518
|
268K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
l
|
518 |
268K |
10 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
518
|
268K
|
10
|
|
NZX - By Stock
|
PEB |
Re:
Ann: GENERAL: PEB: Kaiser Permanente Approves Commercial Use of Cxbladder
|
|
l
|
6 |
2.5K |
0 |
17/06/20 |
17/06/20 |
NZX - By Stock
|
6
|
2.5K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
l
|
1.0K |
498K |
8 |
12/06/20 |
12/06/20 |
ASX - By Stock
|
1.0K
|
498K
|
8
|
|
NZX - By Stock
|
PEB |
Re:
Ann: FLLYR: PEB: Pacific Edge Announces FY20 Results
|
|
l
|
9 |
3.1K |
0 |
10/06/20 |
10/06/20 |
NZX - By Stock
|
9
|
3.1K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
who is still holding?
|
|
l
|
50 |
12K |
0 |
06/06/20 |
06/06/20 |
ASX - By Stock
|
50
|
12K
|
0
|
|
ASX - By Stock
|
VFX |
Re:
who is still holding?
|
|
l
|
50 |
12K |
0 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
50
|
12K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
l
|
1.0K |
498K |
3 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.0K
|
498K
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
l
|
23K |
13M |
6 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
23K
|
13M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
l
|
1.0K |
498K |
6 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
1.0K
|
498K
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
l
|
23K |
13M |
5 |
13/05/20 |
13/05/20 |
ASX - By Stock
|
23K
|
13M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
l
|
518 |
268K |
13 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
518
|
268K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Tracking Valuations
|
|
l
|
322 |
172K |
7 |
04/05/20 |
04/05/20 |
ASX - By Stock
|
322
|
172K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
l
|
18K |
7.0M |
21 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
18K
|
7.0M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
The competition to Remestemcel-L in COVID-19
|
|
l
|
159 |
59K |
9 |
02/05/20 |
02/05/20 |
ASX - By Stock
|
159
|
59K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
l
|
23K |
13M |
4 |
01/05/20 |
01/05/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
A2M |
Re:
China Market Concerns
|
|
l
|
50 |
14K |
11 |
01/05/20 |
01/05/20 |
ASX - By Stock
|
50
|
14K
|
11
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Quarterly Update
|
|
l
|
111 |
23K |
0 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
111
|
23K
|
0
|
|
ASX - By Stock
|
A2M |
Re:
China Market Concerns
|
|
l
|
50 |
14K |
4 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
50
|
14K
|
4
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Quarterly Update
|
|
l
|
111 |
23K |
0 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
111
|
23K
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
l
|
23K |
13M |
10 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
23K
|
13M
|
10
|
|
ASX - By Stock
|
VFX |
Re:
Ann: Appendix 4C - quarterly
|
|
l
|
22 |
6.1K |
3 |
29/04/20 |
29/04/20 |
ASX - By Stock
|
22
|
6.1K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Valuation Musings
|
|
l
|
64 |
38K |
24 |
29/04/20 |
29/04/20 |
ASX - By Stock
|
64
|
38K
|
24
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
l
|
23K |
13M |
8 |
28/04/20 |
28/04/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
l
|
847 |
340K |
0 |
28/04/20 |
28/04/20 |
ASX - By Stock
|
847
|
340K
|
0
|
|